Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review, H2 2017 – iCrowdNewswire
 
x

RSS Newsfeeds

See all RSS Newsfeeds

Dec 7, 2017 2:05 PM ET

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review, H2 2017

iCrowdNewswire - Dec 7, 2017

The “Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review, H2 2017” report has been added to Research and Markets’ offering.

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 27, 30, 22 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 4, 7 and 3 molecules, respectively.

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

– Introduction
– Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Overview
– Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Therapeutics Development
– Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Therapeutics Assessment
– Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Companies Involved in Therapeutics Development
– Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drug Profiles
– Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Dormant Projects
– Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Discontinued Products
– Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Product Development Milestones
– Appendix

For more information about this report visit https://www.researchandmarkets.com/research/k9wfr4/chronic?w=3

Contact Information:

Research and Markets,
Laura Wood,
Senior Manager.
[email protected]
Related Topics: Leukemia Drugs (https://www.researchandmarkets.com/categories.asp?cat_id=209&campaign_id=k9wfr4)

Via iCrowdNewswire
View Related News >